Cargando…

Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis

IMPORTANCE: Progression independent of relapse activity (PIRA) is the main event responsible for irreversible disability accumulation in relapsing multiple sclerosis (MS). OBJECTIVE: To investigate clinical and neuroimaging predictors of PIRA at the time of the first demyelinating attack and factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Tur, Carmen, Carbonell-Mirabent, Pere, Cobo-Calvo, Álvaro, Otero-Romero, Susana, Arrambide, Georgina, Midaglia, Luciana, Castilló, Joaquín, Vidal-Jordana, Ángela, Rodríguez-Acevedo, Breogán, Zabalza, Ana, Galán, Ingrid, Nos, Carlos, Salerno, Annalaura, Auger, Cristina, Pareto, Deborah, Comabella, Manuel, Río, Jordi, Sastre-Garriga, Jaume, Rovira, Àlex, Tintoré, Mar, Montalban, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856884/
https://www.ncbi.nlm.nih.gov/pubmed/36534392
http://dx.doi.org/10.1001/jamaneurol.2022.4655
_version_ 1784873739153833984
author Tur, Carmen
Carbonell-Mirabent, Pere
Cobo-Calvo, Álvaro
Otero-Romero, Susana
Arrambide, Georgina
Midaglia, Luciana
Castilló, Joaquín
Vidal-Jordana, Ángela
Rodríguez-Acevedo, Breogán
Zabalza, Ana
Galán, Ingrid
Nos, Carlos
Salerno, Annalaura
Auger, Cristina
Pareto, Deborah
Comabella, Manuel
Río, Jordi
Sastre-Garriga, Jaume
Rovira, Àlex
Tintoré, Mar
Montalban, Xavier
author_facet Tur, Carmen
Carbonell-Mirabent, Pere
Cobo-Calvo, Álvaro
Otero-Romero, Susana
Arrambide, Georgina
Midaglia, Luciana
Castilló, Joaquín
Vidal-Jordana, Ángela
Rodríguez-Acevedo, Breogán
Zabalza, Ana
Galán, Ingrid
Nos, Carlos
Salerno, Annalaura
Auger, Cristina
Pareto, Deborah
Comabella, Manuel
Río, Jordi
Sastre-Garriga, Jaume
Rovira, Àlex
Tintoré, Mar
Montalban, Xavier
author_sort Tur, Carmen
collection PubMed
description IMPORTANCE: Progression independent of relapse activity (PIRA) is the main event responsible for irreversible disability accumulation in relapsing multiple sclerosis (MS). OBJECTIVE: To investigate clinical and neuroimaging predictors of PIRA at the time of the first demyelinating attack and factors associated with long-term clinical outcomes of people who present with PIRA. DESIGN, SETTING, AND PARTICIPANTS: This cohort study, conducted from January 1, 1994, to July 31, 2021, included patients with a first demyelinating attack from multiple sclerosis; patients were recruited from 1 study center in Spain. Patients were excluded if they refused to participate, had alternative diagnoses, did not meet protocol requirements, had inconsistent demographic information, or had less than 3 clinical assessments. EXPOSURES: Exposures included (1) clinical and neuroimaging features at the first demyelinating attack and (2) presenting PIRA, ie, confirmed disability accumulation (CDA) in a free-relapse period at any time after symptom onset, within (vs after) the first 5 years of the disease (ie, early/late PIRA), and in the presence (vs absence) of new T2 lesions in the previous 2 years (ie, active/nonactive PIRA). MAIN OUTCOMES AND MEASURES: Expanded Disability Status Scale (EDSS) yearly increase rates since the first attack and adjusted hazard ratios (HRs) for predictors of time to PIRA and time to EDSS 6.0. RESULTS: Of the 1128 patients (mean [SD] age, 32.1 [8.3] years; 781 female individuals [69.2%]) included in the study, 277 (25%) developed 1 or more PIRA events at a median (IQR) follow-up time of 7.2 (4.6-12.4) years (for first PIRA). Of all patients with PIRA, 86 of 277 (31%) developed early PIRA, and 73 of 144 (51%) developed active PIRA. Patients with PIRA were slightly older, had more brain lesions, and were more likely to have oligoclonal bands than those without PIRA. Older age at the first attack was the only predictor of PIRA (HR, 1.43; 95% CI, 1.23-1.65; P < .001 for each older decade). Patients with PIRA had steeper EDSS yearly increase rates (0.18; 95% CI, 0.16-0.20 vs 0.04; 95% CI, 0.02-0.05; P < .001) and an 8-fold greater risk of reaching EDSS 6.0 (HR, 7.93; 95% CI, 2.25-27.96; P = .001) than those without PIRA. Early PIRA had steeper EDSS yearly increase rates than late PIRA (0.31; 95% CI, 0.26-0.35 vs 0.13; 95% CI, 0.10-0.16; P < .001) and a 26-fold greater risk of reaching EDSS 6.0 from the first attack (HR, 26.21; 95% CI, 2.26-303.95; P = .009). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that for patients with multiple sclerosis, presenting with PIRA after a first demyelinating event was not uncommon and suggests an unfavorable long-term prognosis, especially if it occurs early in the disease course.
format Online
Article
Text
id pubmed-9856884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-98568842023-02-03 Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis Tur, Carmen Carbonell-Mirabent, Pere Cobo-Calvo, Álvaro Otero-Romero, Susana Arrambide, Georgina Midaglia, Luciana Castilló, Joaquín Vidal-Jordana, Ángela Rodríguez-Acevedo, Breogán Zabalza, Ana Galán, Ingrid Nos, Carlos Salerno, Annalaura Auger, Cristina Pareto, Deborah Comabella, Manuel Río, Jordi Sastre-Garriga, Jaume Rovira, Àlex Tintoré, Mar Montalban, Xavier JAMA Neurol Original Investigation IMPORTANCE: Progression independent of relapse activity (PIRA) is the main event responsible for irreversible disability accumulation in relapsing multiple sclerosis (MS). OBJECTIVE: To investigate clinical and neuroimaging predictors of PIRA at the time of the first demyelinating attack and factors associated with long-term clinical outcomes of people who present with PIRA. DESIGN, SETTING, AND PARTICIPANTS: This cohort study, conducted from January 1, 1994, to July 31, 2021, included patients with a first demyelinating attack from multiple sclerosis; patients were recruited from 1 study center in Spain. Patients were excluded if they refused to participate, had alternative diagnoses, did not meet protocol requirements, had inconsistent demographic information, or had less than 3 clinical assessments. EXPOSURES: Exposures included (1) clinical and neuroimaging features at the first demyelinating attack and (2) presenting PIRA, ie, confirmed disability accumulation (CDA) in a free-relapse period at any time after symptom onset, within (vs after) the first 5 years of the disease (ie, early/late PIRA), and in the presence (vs absence) of new T2 lesions in the previous 2 years (ie, active/nonactive PIRA). MAIN OUTCOMES AND MEASURES: Expanded Disability Status Scale (EDSS) yearly increase rates since the first attack and adjusted hazard ratios (HRs) for predictors of time to PIRA and time to EDSS 6.0. RESULTS: Of the 1128 patients (mean [SD] age, 32.1 [8.3] years; 781 female individuals [69.2%]) included in the study, 277 (25%) developed 1 or more PIRA events at a median (IQR) follow-up time of 7.2 (4.6-12.4) years (for first PIRA). Of all patients with PIRA, 86 of 277 (31%) developed early PIRA, and 73 of 144 (51%) developed active PIRA. Patients with PIRA were slightly older, had more brain lesions, and were more likely to have oligoclonal bands than those without PIRA. Older age at the first attack was the only predictor of PIRA (HR, 1.43; 95% CI, 1.23-1.65; P < .001 for each older decade). Patients with PIRA had steeper EDSS yearly increase rates (0.18; 95% CI, 0.16-0.20 vs 0.04; 95% CI, 0.02-0.05; P < .001) and an 8-fold greater risk of reaching EDSS 6.0 (HR, 7.93; 95% CI, 2.25-27.96; P = .001) than those without PIRA. Early PIRA had steeper EDSS yearly increase rates than late PIRA (0.31; 95% CI, 0.26-0.35 vs 0.13; 95% CI, 0.10-0.16; P < .001) and a 26-fold greater risk of reaching EDSS 6.0 from the first attack (HR, 26.21; 95% CI, 2.26-303.95; P = .009). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that for patients with multiple sclerosis, presenting with PIRA after a first demyelinating event was not uncommon and suggests an unfavorable long-term prognosis, especially if it occurs early in the disease course. American Medical Association 2022-12-19 2023-02 /pmc/articles/PMC9856884/ /pubmed/36534392 http://dx.doi.org/10.1001/jamaneurol.2022.4655 Text en Copyright 2022 Tur C et al. JAMA Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Tur, Carmen
Carbonell-Mirabent, Pere
Cobo-Calvo, Álvaro
Otero-Romero, Susana
Arrambide, Georgina
Midaglia, Luciana
Castilló, Joaquín
Vidal-Jordana, Ángela
Rodríguez-Acevedo, Breogán
Zabalza, Ana
Galán, Ingrid
Nos, Carlos
Salerno, Annalaura
Auger, Cristina
Pareto, Deborah
Comabella, Manuel
Río, Jordi
Sastre-Garriga, Jaume
Rovira, Àlex
Tintoré, Mar
Montalban, Xavier
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
title Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
title_full Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
title_fullStr Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
title_full_unstemmed Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
title_short Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
title_sort association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856884/
https://www.ncbi.nlm.nih.gov/pubmed/36534392
http://dx.doi.org/10.1001/jamaneurol.2022.4655
work_keys_str_mv AT turcarmen associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT carbonellmirabentpere associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT cobocalvoalvaro associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT oteroromerosusana associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT arrambidegeorgina associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT midaglialuciana associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT castillojoaquin associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT vidaljordanaangela associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT rodriguezacevedobreogan associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT zabalzaana associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT galaningrid associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT noscarlos associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT salernoannalaura associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT augercristina associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT paretodeborah associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT comabellamanuel associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT riojordi associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT sastregarrigajaume associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT roviraalex associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT tintoremar associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis
AT montalbanxavier associationofearlyprogressionindependentofrelapseactivitywithlongtermdisabilityafterafirstdemyelinatingeventinmultiplesclerosis